Abstract 5883
Background
Diffuse Large B-Cell Lymphoma is the most common type of Non-Hodgkin Lymphoma. Genetic studies have revealed that one of its molecular subtypes resistant to treatment by standard protocols occurs when there are concurrent translocations in the C-MYC and BCL2 or BCL6 genes constituting the type known as double hit lymphoma (DHL). Double expresser lymphoma (DEL) is another subtype that is much more frequent, including about 20-30% of cases. It occurs when there is protein overexpression of C-MYC together with BCL2 or BCL6 proteins without actual gene translocation.
Methods
Tissue microarray platform was constructed using cores from selected areas of each specimen. Hematoxylin and Eosin slides were reviewed for confirmation of pathologic diagnosis and immunohistochemistry was used for detection of C-MYC, BCL2 and BCL6 expression. Stained slides were assessed for percentage of cellular expression for each marker where median expression was used as the threshold value for defining positivity. DLBCL with high expression for MYC and BCL2 or BCL6 was defined as DEL.
Results
Tissue microarray blocks were constructed from the paraffin blocks of 87 cases with a confirmed diagnosis of DLBCL. Median age for participants was 58 years. CMYC, BCL2, and BCL6 showed high protein expression in 50.6% (n = 44), 55.2% (n = 48), and 54% (n = 47) respectively. Cases with DEL constituted 44.8% of sample (n = 39), where DEL was significantly higher in patients with poor performance status (PS > 1). Neither of the associations between DEL and other patients’ or disease’s characteristics (age, gender, smoking history, family history, comorbidities, B symptoms, LDH, B2 microglobulin, stage, BM infiltration, presence of more than one extranodal site, IPI, and risk group) tested positive. There were no associations between DEL and response, PFS, DFS, or OS.
Conclusions
DEL is not uncommon among studied sample constituting around 44.8% of cases. This positive protein expression was commonly found in patients with poor performance status creating a particular therapeutic challenge. DEL did not correlate with other variables including known prognostic factors for DLBCL. DEL did not also show effect on further treatment outcomes including response and survival.
Clinical trial identification
N/A
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2171 - CCND1 Amplification Contributes to Immunosuppression in Head and Neck Squamous Cell Carcinoma and the Association with a Poor Response to Immune Checkpoint Inhibitors
Presenter: Chloe Huang
Session: Poster Display session 3
Resources:
Abstract
2624 - Efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation
Presenter: Hui-Juan Cui
Session: Poster Display session 3
Resources:
Abstract
3494 - Neutrophil to Lymphocyte Ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N).
Presenter: Audrey Simonaggio
Session: Poster Display session 3
Resources:
Abstract
3964 - Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours
Presenter: Alexandra Pender
Session: Poster Display session 3
Resources:
Abstract
3041 - Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer Phase I IO Cohort
Presenter: Daniel Araujo
Session: Poster Display session 3
Resources:
Abstract
3910 - Analysis of Molecular Profile Complexities for Immunotherapy Decision Support
Presenter: Robert Dóczi
Session: Poster Display session 3
Resources:
Abstract
4836 - The Role of Tumor Neoantigens in the Differential Response to Immunotherapy (IO) in EGFR and BRAF Mutated Lung Cancers - Quantity or Quality?
Presenter: Katrina Case
Session: Poster Display session 3
Resources:
Abstract
1929 - Impact of previous corticosteroid (CS) exposure on efficacy of Programmed Cell Death-(Ligand) 1 blockade in patients with advanced Non-Small-Cell Lung Cancer (NSCLC): a single Center retrospective analysis
Presenter: Fabrizio Nelli
Session: Poster Display session 3
Resources:
Abstract
2601 - Comparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors
Presenter: Sabrina Vari
Session: Poster Display session 3
Resources:
Abstract
3628 - Predictive model for survival in advanced non-small-cell lung cancer (NSCLC) treated with frontline pembrolizumab
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 3
Resources:
Abstract